Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy

Yuhao Cheng1,*, Hao Cheng1,*, Chenxiao Jiang1, Xuefeng Qiu1, Kaikai Wang1, Wei Huan1, Ahu Yuan1, Jinhui Wu1 & Yiqiao Hu1,2

Photodynamic therapy (PDT) kills cancer cells by converting tumour oxygen into reactive singlet oxygen ($^1$O$_2$) using a photosensitizer. However, pre-existing hypoxia in tumours and oxygen consumption during PDT can result in an inadequate oxygen supply, which in turn hampers photodynamic efficacy. Here to overcome this problem, we create oxygen self-enriching photodynamic therapy (Oxy-PDT) by loading a photosensitizer into perfluorocarbon nanodroplets. Because of the higher oxygen capacity and longer $^1$O$_2$ lifetime of perfluorocarbon, the photodynamic effect of the loaded photosensitizer is significantly enhanced, as demonstrated by the accelerated generation of $^1$O$_2$ and elevated cytotoxicity. Following direct injection into tumours, in vivo studies reveal tumour growth inhibition in the Oxy-PDT-treated mice. In addition, a single-dose intravenous injection of Oxy-PDT into tumour-bearing mice significantly inhibits tumour growth, whereas traditional PDT has no effect. Oxy-PDT may enable the enhancement of existing clinical PDT and future PDT design.
Photodynamic therapy (PDT) depends on the ability of photosensitizers (PS) to transfer energy from lasers to tumour-dissolved oxygen (O$_2$) to generate cytotoxic singlet oxygen ($^1$O$_2$) for cancer treatment. However, the effectiveness of PDT is impaired by an inadequate oxygen supply in tumours. In most solid tumours, hypoxia is common because the oxygen supply is reduced by disturbed microcirculation and deteriorated diffusion. Moreover, PDT worsens hypoxia through oxygen consumption and vascular shutdown effects. Low oxygen content can reduce the photodynamic efficacy of PS, preventing PDT from achieving its full therapeutic potential.

Traditional methods have attempted to optimize tumour oxygenation to ensure PDT efficacy. For example, dividing irradiation into light–dark circles and extending irradiation with a low fluence rate have both been investigated as techniques for better tumour reoxygenation by the blood. However, these approaches only affect PDT-induced oxygen depletion, whereas the pre-existing hypoxia cannot be reversed; moreover, vascular shutdown due to PDT would also result in severe hypoxia. Hyperbaric oxygen inhalation has also been used to actively increase the level of tumour oxygen. However, vascular damage during PDT still prevents further oxygenation from hyperbaric blood; moreover, the potential toxic effects of excessive oxygen are an impediment to its clinical use. To our knowledge, no existing techniques can effectively reverse the tumour oxygen content during PDT. Therefore, optimizing the efficacy with limited oxygen is of great importance for photodynamic therapy.

To address this challenge, herein we load photosensitizer into perfluorocarbon nanodroplets to develop a novel oxygen self-enriched photodynamic therapy (Oxy-PDT). Because of its high oxygen capacity, perfluorocarbon can maintain a higher oxygen content than the tumour matrix at a given oxygen partial pressure. Thus, although the tumour oxygen content remains limited during PDT, sufficient O$_2$ can always be enriched in the PFC droplet for photodynamic consumption by the loaded PS, thus obtaining improved efficacy. This type of enhancement is possible regardless of pre-existing hypoxia, photodynamic consumption, or vascular damage; moreover, it has been reported that the $^1$O$_2$ lifetime in perfluorocarbon is much longer than in the cellular environment or in water, which results in long-lasting photodynamic effects. Therefore, Oxy-PDT might help PS to achieve its full therapeutic potential. In this study, we assessed the therapeutic efficacy of Oxy-PDT as a novel form of PDT in cancer models. First, we studied the photodynamic effect of Oxy-PDT on the generation of $^1$O$_2$ and its cytotoxicity by incubating tumour cells with Oxy-PDT, which were then irradiated with laser beams. Next, we assessed the effect of Oxy-PDT on tumour growth by intratumoural injections in vivo. Lastly, we examined the passive targeting of Oxy-PDT by intravenous injections in vivo. We envision that this new approach may guide improvements in the clinical use of PDT.

Results

Synthesis of the Oxy-PDT agent. The near-infrared photosensitiser IR780 (Fig. 1b) and perfluorohexane (PFH) were used in this manuscript to prepare the Oxy-PDT agent LIP(IR780 + PFH). IR780 is uniformly dispersed in a lipid monolayer (composed of lecithin, cholesterol, and DSPE-PEG2000), and the average diameter of the resulting nanodroplets is 200 nm (Fig. 1c). As the Oxy-PDT agent is irradiated by a near-infrared (NIR) 808-nm laser, IR780 transfers energy to the oxygen enriched in the PFH, producing cytotoxic singlet oxygen (Fig. 1a). The existence of IR780 in the Oxy-PDT agent was confirmed by the absorption peak in the NIR region (Supplementary Fig. 2). The existence of PFH in the Oxy-PDT agent was confirmed by the contrast enhancement in the ultrasound image, whereas LIP(IR780), pure PFH, and water produced blank echo signals (Fig. 1d). PFH in Oxy-PDT agent was also confirmed by GC-Mass (Supplementary Fig. 2b,c). The stability and self-quenching capability of the Oxy-PDT agent were then evaluated (Supplementary Fig. 3). The results indicate that Oxy-PDT can increase the dark stability of IR780 and reduce its self-quenching.

Characterization of photodynamic efficacy. We compared the $^1$O$_2$ generation by Oxy-PDT with traditional PDT, as determined by the fluorescence intensity of oxidized SOSG (an indicator of $^1$O$_2$). In the presence of $^1$O$_2$, the oxidation of SOSG results in increased fluorescence and therefore provides a means of monitoring $^1$O$_2$ production. We measured the varying extent of fluorescence gain in water in the presence of LIP(IR780 + PFH) or LIP(IR780) irradiated by an 808-nm laser for 5-s intervals (Fig. 2a). The presence of LIP(IR780 + PFH) resulted in the highest rate of fluorescence gain, and the total accumulation was also significantly higher than in the presence of LIP(IR780), which resulted in only a marginal fluorescence gain (P<0.05, two-sided Student’s t-test). The singlet oxygen quantum yields ($\Phi_w$) of both LIP(IR780) and LIP(IR780 + PFH) were also calculated (Supplementary Table 1). The $\Phi_w$ value of LIP(IR780 + PFH) is higher than for LIP(IR780) or IR780, indicating that the Oxy-PDT platform can increase the quantum yield of photosensitizer. Moreover, this phenomenon can also be achieved using other photosensitizers, suggesting that the enhancement is not specific to IR780 (Supplementary Fig. 4).

To determine whether such fluorescence gain is a result of the presence of PFH, we diluted LIP(IR780 + PFH) and LIP(IR780) to a series of solutions with concentrations of PFH ranging from 30 v/v% to 1.88 v/v% (Fig. 2b). The dilution caused a marked relative reduction in the fluorescence between 20 s continually irradiated LIP(IR780 + PFH) and LIP(IR780), from 12.2- to 0.84-fold. Moreover, the enhancement was proven to be independent
of IR780 concentration (Supplementary Fig. 5), indicating that the presence of PFH is a key factor in the enhanced PDT effect. Then, when we added enough PFH (resulting in 30 v/v% PFH) to the diluted LIP(IR780 + PFH), the relatively reduced fluorescence recovered (Fig. 2c), confirming the participation of PFH in the generation of $^1\text{O}_2$.

We then tested the photodynamic efficacy of both LIP(IR780) and LIP(IR780 + PFH) in different hypoxic conditions (Fig. 2c). The samples were exposed to different atmospheres (containing 0.1, 1, 7 and 21 kPa $\text{O}_2$) and then received 20 s irradiation. The results suggested that LIP(IR780 + PFH) significantly enhanced $^1\text{O}_2$ production under different oxygen pressures. Meanwhile, LIP(IR780 + PFH) in extremely hypoxic conditions (0.1 kPa $\text{O}_2$) showed higher $^1\text{O}_2$ generation than LIP(IR780) in non-hypoxic conditions (21 kPa $\text{O}_2$), indicating that during Oxy-PDT treatment, the PFC can successfully enrich oxygen to accelerate $^1\text{O}_2$ generation.

**Cell assays.** Assays were performed on both MCF-7 human breast cancer cells and CT26 murine colon adenocarcinoma cells. First, we examined the production of reactive oxygen species (ROS) such as $^1\text{O}_2$ from Oxy-PDT and traditional PDT in live cells using carboxy-$\text{H}_2\text{DCFDA}$ as a fluorescent marker for ROS. Carboxy-$\text{H}_2\text{DCFDA}$ permeates cell membranes to be oxidized, emitting bright green fluorescence in the presence of $^1\text{O}_2$. The resulting oxidatively stressed cells showed green fluorescence, indicating increased $^1\text{O}_2$ gain. We treated cells with PBS, LIP(IR780) or LIP(IR780 + PFH), and with and without 20 s continual 808-nm laser irradiation. Without laser irradiation, MCF-7 cells treated with PBS, LIP(IR780) or LIP(IR780 + PFH) showed negligible fluorescence (Fig. 3a,b). After irradiation, cells treated with LIP(IR780 + PFH) showed significant green fluorescence, whereas cells treated with PBS and LIP(IR780) still showed negligible fluorescence. Similar results can also be observed in treated CT26 cells (Supplementary Fig. 6). To verify the results, flow cytometry was used to analyse the percentage of cells stained with green fluorescence (Fig. 3c). Cells treated with PBS, LIP(IR780) and LIP(IR780 + PFH) showed a relatively low percentage (2.84%, 9.69% and 13.2%, respectively) of green fluorescent cells, whereas cells treated with LIP(IR780) showed an increased percentage (24.7%) after irradiation. More notably, the percentage (41.0%) in cells treated with LIP(IR780 + PFH) and an 808-nm laser was much higher than in cells treated with LIP(IR780), indicating the better performance of LIP(IR780 + PFH) as the $^1\text{O}_2$ producer.

After comparing their performances as $^1\text{O}_2$ producers, we tested Oxy-PDT and traditional PDT for their photodynamic effects on inducing cell death. Without laser irradiation, we found no significant cytotoxicity in MCF-7 cells treated with LIP(IR780) or LIP(IR780 + PFH) (Fig. 4a). After 20 s continual irradiation by an 808-nm laser, we detected a reduction in the viability of cells treated with both LIP(IR780) and LIP(IR780 + PFH). It is notable that the reductions in viability were higher in cells treated with LIP(IR780 + PFH) than in cells treated with LIP(IR780) when the concentrations of IR780 were higher than 2.09 µg ml$^{-1}$ ($P < 0.05$, two-sided Student's t-test).
two-sided Student’s t-test). Similar results were also observed in CT26 murine colon adenocarcinoma cells (Fig. 4b). In addition, cell death induced by photothermal effects was not evident in the minimal IR780 and irradiation dosages (Supplementary Fig. 7a).

The effects of Oxy-PDT in hypoxia were also studied (Fig. 4c). CT26 cells were placed in a hypoxic transparent box for 4 h before irradiation. Then, laser irradiation and a further 1-h incubation were performed. Interestingly, in hypoxic conditions, Oxy-PDT still maintained superior cytotoxicity to traditional PDT (P < 0.05, two-sided Student’s t-test), indicating that Oxy-PDT can improve the efficacy of PDT in both normal and hypoxic conditions.

**In vivo PDT using intratumoural injection.** The *in vivo* $^1$O$_2$ generation of both LIP(IR780) and LIP(IR780 + PFH) was measured. SOSG was also used as an indicator because of its green fluorescence after oxidization by the generated $^1$O$_2$. Without laser irradiation, tumours treated with LIP(IR780) or LIP(IR780 + PFH) showed negligible fluorescence. After laser irradiation, tumours treated with LIP(IR780) or LIP(IR780 + PFH) showed significant green fluorescence, whereas tumours treated with LIP(IR780) showed weak fluorescence (Fig. 5a). This result indicated that higher $^1$O$_2$ generation by Oxy-PDT can also be achieved *in vivo*.

We further compared the efficacy of Oxy-PDT and traditional PDT *in vivo* on CT26 tumour-bearing mice via intratumoural injections. The mice were divided into five groups, including a
there was incomplete tumour cell death, suggesting the successful destruction of tumour cells by Oxy-PDT. At 14 days after treatment, a biodistribution study of the mice receiving only the intratumoural injection of LIP(IR780 + PFH) and irradiation showed the presence of IR780 only in the tumour tissues (Fig. 5e), suggesting that IR780 remained primarily in the tumour mass after administration and that the diffusion from tumour tissue to other tissues was negligible.

In vivo PDT using intravenous injection. After the study of intratumoural injection, we examined the efficacy of Oxy-PDT by intravenous injection. Because of the enhanced permeability and retention effect, nanoparticles in the range of 10–400 nm can accumulate in tumour tissue at levels 70 times higher than in normal tissue20,21. Accordingly, LIP(IR780 + PFH) with a mean particle size of 200 nm showed passive tumour targeting, as demonstrated by the NIR (Supplementary Fig. 8) and the ultrasound imaging of tumour accumulation after intravenous injection. The tumour accumulation of IR780 reached its maximum at 24 h after intravenous injection (Fig. 6a); meanwhile, ultrasound imaging confirmed the existence of PFH in the tumours at 24 h (Fig. 6b). Therefore, 24 h after intravenous injection was chosen for 808-nm laser irradiation.

Mice were divided into five groups, including the saline control group and the LIP (IR780) and LIP (IR780 + PFH) groups with and without 808-nm laser irradiation. To avoid the confounding effects of the tumour during irradiation was controlled by dividing the irradiation time into two consecutive 10 s applications with an 1-min interval in between (Supplementary Fig. 7b). We first evaluated the efficacy of the treatment in terms of tumour cell apoptosis by performing TUNEL staining on histological sections from the different treatment groups immediately after drug administration. We found a greater number of apoptotic cells in histological sections from the group receiving LIP(IR780 + PFH) and irradiation (Fig. 5b), which suggested the successful destruction of tumour cells by Oxy-PDT.

We then assessed the photodynamic effects of each group by monitoring the tumour volumes over a period of 2 weeks (Fig. 5d, Supplementary Data 1). The tumour volumes in mice receiving LIP(IR780 + PFH) with 808-nm laser irradiation were significantly inhibited, whereas no significant differences in tumour volumes were found between the saline control group and other treatment groups, including LIP(IR780 + PFH) and LIP(IR780) with and without laser irradiation. We then performed H&E staining on tissue sections from each group at 14 days after treatment. We found that most tumour cells were severely damaged or destroyed in mice treated with LIP(IR780 + PFH) and irradiation by an 808-nm laser (Fig. 5c). In the other groups, there was incomplete tumour cell death, suggesting the successful saline control group and LIP(IR780) and LIP(IR780 + PFH) groups with and without 808-nm laser irradiation. To avoid the additional efficacy induced by photothermal effects, the temperature of the tumour during irradiation was controlled by dividing the irradiation time into two consecutive 10 s applications with a 1-min interval in between (Supplementary Fig. 7b). We first evaluated the efficacy of the treatment in terms of tumour cell apoptosis by performing TUNEL staining on histological sections from the different treatment groups immediately after drug administration. We found a greater number of apoptotic cells in histological sections from the group receiving LIP(IR780 + PFH) and irradiation (Fig. 5b), which suggested the successful destruction of tumour cells by Oxy-PDT.

In vivo photodynamic therapy of Oxy-PDT by intratumoural injection in a subcutaneous tumour model. (a) SOSG staining in tumour sections for $^{1}$O$_{2}$ determination (scale bar, 100 $\mu$m). Before sectioning, a mixture of SOSG with saline, LIP(IR780), or LIP(IR780 + PFH) was injected into the tumours, followed by laser irradiation. (b) TUNEL staining for apoptosis in tumour sections from each group to determine the effectiveness of Oxy-PDT. DAPI counterstaining indicates the tumour nuclear region (scale bar, 50 $\mu$m). (c) H&E staining for pathological changes in tumour sections from each group to determine the effectiveness of Oxy-PDT (scale bar, 50 $\mu$m). (d) Changes in tumour volumes used to assess the effectiveness of Oxy-PDT in tumour-bearing mice by intratumoural injection. Values are the means ± s.e.m. (n = 6, * P<0.05 versus LIP(IR780) + NIR, two-sided Student’s t-test). (e) Biodistribution of intratumourally injected LIP(IR780 + PFH) in organs of mice at 14 days after initial treatment. Organs were isolated and quantified by near-infrared imaging (based on IR780 content). Values are the means ± s.e.m. (n = 6).
induced by photothermal radiation, the temperature of the tumour during irradiation was controlled within a safe range by dividing the irradiation time into two consecutive 10-s applications with a 1-min interval (Supplementary Fig. 7b). Monitoring the change in tumour volume as a function of time after treatment revealed a significant reduction in the tumour growth rate of mice receiving LIP(IR780 + PFH) and laser irradiation (P < 0.05, versus LIP(IR780) + NIR, two-sided Student’s t-test, Fig. 6c, Supplementary Data 2). No significant reduction was found in the tumour growth rate of mice receiving LIP(IR780) and laser irradiation. At the end point of day 10, the tumours from each mouse were excised and weighed (Fig. 6d).

Discussion

In this study, we demonstrate a novel Oxy-PDT platform for achieving enhanced efficacy. PDT depends strongly on O2 to kill cancer cells, and thus the O2 generation rate determines PDT efficacy. In the Oxy-PDT agent, both PS and oxygen are enriched in the nanodroplet, and thus the oxygen available for the photodynamic reaction are increased compared with traditional PDT in the tumour matrix. Moreover, the lifetime of O2 varies with the polarity of the solvent: the half-life of O2 is ~6 × 10^-7 s in the cellular environment, 5 × 10^-6 s in water, and 5 × 10^-2 s in PFH19. Therefore, by using a PFC nanodroplet as the PS carrier, the lifetime of O2 is extended. These phenomena may be two major reasons that Oxy-PDT can enhance the reactive oxygen level.

NIR dyes (such as IR780) typically have a lower O2 quantum yield (ΦO2) than visible dyes because the wavelength of NIR light (>800 nm) is longer than the wavelength of visible light and may have insufficient energy to excite oxygen to its singlet state1,2,27. However, in this study, ΦO2,LIP(IR780 + PFH) was found to be higher than ΦO2,LIP(IR780), demonstrating that the Oxy-PDT platform can increase the O2 quantum yield of NIR dyes. Furthermore, our results showed that Oxy-PDT could increase the dark stability of IR780 and reduce its self-quenching.

The results also showed a higher therapeutic efficacy of Oxy-PDT than traditional PDT both in vitro and in vivo. With direct injection into tumours, the in vivo studies showed complete

Figure 6 | In vivo photodynamic therapy of Oxy-PDT by intravenous injection in a subcutaneous tumour model. (a) Near-infrared imaging of tumour accumulation of IR780 in tumour-bearing mice after intravenous injection of LIP(IR780 + PFH). Images were taken at 0, 12, 24 and 32 h postinjection. Tumours are circled with white dashed lines. (b) Ultrasound imaging of tumours on mice before (0 h) and after intravenous injection (24 h) of LIP(IR780 + PFH) (0.2 ml, 60 μg ml^-1 IR780, 10 %PFH), LIP(IR780) (0.2 ml, 60 μg ml^-1 IR780), and saline. Tumours are circled with white dashed lines. (c) Changes in tumour volumes used to assess the effectiveness of Oxy-PDT in tumour-bearing mice by intravenous injection. Treatments were performed only once. Values are the means ± s.e.m. (n = 6, *P < 0.05 versus LIP(IR780 + PFH), two-sided Student’s t-test). (d) Average weights of tumours at day 10. Mice were killed, and tumours were isolated for weighing. Values are the means ± s.e.m. (n = 6, *P < 0.05 versus LIP(IR780) + NIR, two-sided Student’s t-test).
tumour growth inhibition in Oxy-PDT mice treated with a low photosensitizer dosage and 20-s laser irradiation, whereas traditional PDT showed negligible tumour inhibition. These results suggested that in Oxy-PDT, PFH can help the photosensitizer achieve improved effects. The ultraviolet-visible absorption of the NIR dye is reduced after laser irradiation, possibly due to the degradation of the NIR dye by exposure to O2. Although the degradation products might also be toxic to cells, the enhanced tumour growth effect of LIP(IR780 + PFH) is still attributed to PFH because the possible degradation product is also present in LIP(IR780). Interestingly, with only a single-dose intravenous injection into tumour-bearing mice, Oxy-PDT still exhibited significant tumour inhibition, indicating that passive targeting plays an important role in the therapeutic efficacy. It should be noted that in all our experiments, the influence of photothermal therapy has been excluded to examine only photodynamic effects. Moreover, previous studies have already confirmed the high oxygen content in perfluorocarbons, which are used as artificial blood in clinical applications and can be used as ultrasonic contrast agents and MR contrast agents to monitor the behavior of Oxy-PDT agents in vivo.

As previously discussed, Oxy-PDT is considered to be the first PDT design that can realize high efficacy in hypoxic conditions. This Oxy-PDT approach with self-enriching oxygen offers a simple yet effective treatment option for cancer patients. We have provided a proof of concept for the PFC/photosensitizer-loaded emulsion as an agent of improved PDT in vivo and anticipate its wide clinical application after dose optimization.

**Methods**

**Chemicals and reagents.** Lecithin and cholesterol were purchased from Aladdin Industrial Corporation, and DSPE-PEG2000 was obtained from A.V.T. Pharm. Ltd., Shanghai, China. The 99% perfluorohexane was purchased from Bailingwei Tech Co., Ltd. (Beijing, China). IR780 was purchased from Sigma-Aldrich Chemical Corporation (St Louis, MO, USA). Singlet Oxygen Sensor Green was obtained from Molecular Probes, Inc. Carboxy-H2DCFDA was purchased from Invitrogen (USA). Cell counting kit-8 (CCK-8) was supplied by Dojindo Laboratories (Japan). MCF-7 and CT-26 cells were purchased from the Cell Bank of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). All of the BALB/c mice were purchased from Yangzhou University Medical Centre (Yangzhou, China). All of the chemicals were used as supplied without further purification.

**Synthesis of the Oxy-PDT agent.** First, 24.65 mg lecithin, 4.28 mg cholesterol, 3.79 mg DSPE-PEG2000, and the specified IR780 were dissolved in 5 ml dichloromethane. The dichloromethane was removed from a 25-ml round flask by rotary evaporation to form lipid films. Using 10-min sonication, 1.4 ml pure water was added, and the film was peeled off. Next, 0.6 ml PFH was added gradually under high-speed stirring. After centrifugation at 725, Germany, 10000 rpm for 10 min, the solution was reconstituted in an ice bath for 10 min to form 2 ml LIP(IR780 + PFH) (30 v/v% PFH). LIP(IR780) can be formed by the addition of pure water instead of PFH.

**Detection of singlet oxygen in vitro.** First, 0.1 ml samples and 0.02 ml of 50 μM SOSG were mixed in black 96-well plates (Costar). After irradiation (808-nm, 2 W cm−2), the oxidized SOSG was quantified by measuring the fluorescence intensity (excited at 504 nm and measured at 525 nm) using a multifunctional microplate reader (Safire, TECAN). As for the production of singlet oxygen in PDT treatments were performed on 4- to 6-week-old BALB/C male mice. When the tumour volume reached ~1,000 mm3, the following study was performed. A mixture of 25 μl SOSG (50 μM), 25 μl saline, and LIP(IR780) (156 μg ml−1 IR780) or LIP(IR780 + PFH) (156 μg ml−1 IR780, 30 v/v% PFH) was directly injected into tumours. Subsequently, laser treatment (with an 808-nm laser (2 W cm−2) for two consecutive exposures of 10 s each, with a 1-min interval between the two irradiations) was performed on the LIP(IR780) + NIR and LIP(IR780 + PFH) + NIR groups to generate 1O2. Then, the mice were photographed at days 7 and 14. At 14 days after treatment, the tumour, heart, liver, spleen, lung, kidney and brain tissues of mice from group 5 were collected and cryosectioned on slides at a 7 μm thickness. The fluorescence emission of the oxidised SOSG (Ex/Em = 504/525 nm) was captured by fluorescence microscope.

**PDT in tumour-bearing mice by intratumoral injection.** PDT treatments were then performed on 4- to 6-week-old BALB/C male mice. When the tumour volume reached ~1,000 mm3, the following study was performed. A mixture of 25 μl SOSG (50 μM), 25 μl saline, and LIP(IR780) (156 μg ml−1 IR780) or LIP(IR780 + PFH) (156 μg ml−1 IR780, 30 v/v% PFH) was directly injected into tumours. Subsequently, laser treatment (with an 808-nm laser (2 W cm−2) for two consecutive exposures of 10 s each, with a 1-min interval between the two irradiations) was performed on the LIP(IR780) + NIR and LIP(IR780 + PFH) + NIR groups to generate 1O2. Then, the mice were photographed at days 7 and 14. At 14 days after treatment, the tumour, heart, liver, spleen, lung, kidney and brain tissues of mice from group 5 were collected and cryosectioned on slides at a 7 μm thickness. The fluorescence emission of the oxidised SOSG (Ex/Em = 504/525 nm) was captured by fluorescence microscope.

**Cytotoxicity.** The MCF-7 or CT26 cells were seeded into 96-well plates at a density of 4 × 104 cells per well. After incubation for 24 h, the cells were treated with LIP(IR780) or LIP(IR780 + PFH) at different concentrations (final concentrations of 20 μl samples mixed with 100 μl culture medium). For cytotoxicity in hypoxia, the cells were put into a GENbox Jar, where GENbox aneur and anaerobic atmosphere indicator were included. As the oxygen was consumed by GENbox aneur, the indicator changed its colour from blue to colourless. The Jar was approximately oxygen-free 4 h later. Then, the cells were immediately irradiated by an 808-nm laser (2 W cm−2) for 20 s per well. After co-incubation for 2 h, the drugs were removed, and fresh culture medium was added. After further incubation for 24 h, a mixed solution consisting of CCK-8 (10 μl) and fresh culture medium (100 μl) was added to each well and incubated for 2 h at 37°C. Finally, the absorbance was measured at 450 nm using the microplate reader. Cells without any drugs or NIR irradiation were used as a negative control.

**Animals.** BALB/C male mice aged 4–6 weeks were purchased from Yangzhou University Medical Centre (Yangzhou, China) and were used in accordance with the regulations of the Institutional Animal Care and Use Committee (IACUC) of Nantong University. During the study, animals were observed for any clinically relevant abnormalities daily or once every other day. If any animal was moribund due to treatment-associated toxicity, tumour over-growth (≥3,000 mm3), then the loss of 20% of body weight relative to the start of the study, or the appearance of large or open ulceration in the xenograft before scheduled killing, it was killed by CO2 inhalation. In several instances, however, tumour volumes were allowed to exceed the stated limit of 3,000 mm3 because the affected mice appeared otherwise healthy and had lost <5% of their original body weight. This implementation of the protocol has been confirmed by NJU-IACUC. Hairs on the flanks of the mice were removed before further treatments. Tumours were first developed in BALB/C mice by subcutaneously implanting 1 × 106 CT26 cells suspended in 100 μl of serum-free DMEM in the lower flanks of the mice. When the tumour volume reached ~200 mm3, the tumour mass was removed and cut into small pieces of approximately 2–6 mm3, which were subcutaneously implanted into other mice.
Tumours from the five groups were cryosectioned at 7-μm thickness onto slides and stained with HE and according to the manufacturer's instructions.

**PDT in tumour-bearing mice by intravenous injection.** The CT26 subcutaneous tumours were first developed in the mice as described above. PDT treatment was then performed at 8 days after inoculation of the tumour pieces. The average initial tumour volume was 144.4 mm³. The testing groups were as follows: group 1: saline; group 2: LIP(IR780); group 3: LIP(IR780) + NIR; group 4: LIP(IR780 + PFH); group 5: LIP(IR780 + PFH) + NIR. First, 200 μL of LIP(IR780) (60 μg mL⁻¹ IR780), LIP(PFH + IR780) (60 μg mL⁻¹ IR780, 10 v/v% PFH) or saline alone were intravenously injected. NIR images of IR780 accumulation in the tumours of the mice in the LIP(IR780 + PFH) group were taken at 0, 12, 24 and 32 h, and ultrasound images of the tumour accumulation of PFH were taken pre- and 24-h postinjection. Twenty-four hours later, laser treatment was performed on groups 3 and 5 by irradiating the tumour region with an 808-nm laser (2 W cm⁻²) for two consecutive exposures of 10 s each, with a 1-min interval between the two irradiations for tumour cooling. Tumour size was measured every two days using a vernier calliper for 10 days after the first PDT treatment. The tumours were measured for the maximum width (X) and length (Y) and the tumour volumes (V) were calculated using the formula: \( V = \frac{X \times Y^2}{2} \). Changes in tumour volume as a function of time were determined for each mouse by normalizing the tumour volume at day X to the respective tumour volume at day 0 after treatment. Mice were randomly selected in each group, and the tumours were photographed at day 0, 5 and 10. At 10 days after treatment, the mice in each group were killed, and the tumours were removed, photographed and weighed.

**Statistical analysis.** Statistical analysis was performed by two-sided Student’s t-test for two groups, and one-way analysis of variance for multiple groups. A value of \( P < 0.05 \) was considered statistically significant.

**References**

1. Agostinis, P. et al. Photodynamic therapy of cancer: an update. *CA. Cancer J. Clin.* **61**, 250–281 (2011).
2. Celli, J. P. et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. *Chem. Rev.* **110**, 2795–2838 (2010).
3. Maas, A. L. et al. Tumour vascular microenvironment determines responsiveness to photodynamic therapy. *Cancer Res.* **72**, 2079–2088 (2012).
4. Henderson, B. W. & Fingar, V. H. Relationship of tumour hypoxia and response to photodynamic therapy in an experimental mouse tumour. *Cancer Res.* **47**, 3110–3114 (1987).
5. Hockel, M. & Vaupel, P. Tumour hypoxia: definitions and current clinical, biologic, and molecular aspects. *J. Natl Cancer Inst.* **93**, 266–276 (2001).
6. Wang, W., Moriyama, L. T. & Bagnato, V. S. Photodynamic therapy induced vascular damage: an overview of experimental PDT. *Laser Phys. Lett.* **10**, 023001–023008 (2013).
7. Henderson, B. W. & Dougherty, T. J. How does photodynamic therapy work. *Photochem. Photobiol.* **55**, 145–157 (1992).
8. Curnow, A., McIroy, B. W., Postle-Hacon, M. J., MacRobert, A. J. & Bown, S. G. Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. *Photochem. Photobiol.* **69**, 71–76 (1999).
9. Sita, T. M., Hampton, J. A. & Henderson, B. W. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. *Br. J. Cancer* **77**, 1386–1394 (1998).
10. Busch, T. M., Wang, H. W., Wileyto, E. P., Yu, G. Q. & Bunte, R. M. Increasing damage to tumour blood vessels during motexafin lutetium-pdt through use of low fluence rate. *Radiat. Res.* **174**, 331–340 (2010).
11. Tomaszewski, M., Maier, A., Pinter, H., Stranzl, H. & Smolle-Juttner, F. M. Photodynamic therapy enhanced by hyperbaric oxygen in acute endoluminal palliation of malignant bronchial stenosis (clinical pilot study in 40 patients). *Eur. J. Cardiothorac. Surg.* **19**, 549–554 (2001).
12. Jirsa, Jr M., Pouckova, P., Dolezal, J., Pospisil, J. & Jirsa, M. Hyperbaric oxygen and photodynamic therapy in tumour-bearing nude mice. *Eur. J. Cancer* **27**, 109 (1991).
13. Maier, A. et al. Hyperbaric oxygen and photodynamic therapy in the treatment of advanced carcinoma of the cardia and the esophagus. *Lasers Surg. Med.* **26**, 308–315 (2000).
14. Maier, A. et al. Does hyperbaric oxygen enhance the effect of photodynamic therapy in patients with advanced esophageal carcinoma? A clinical pilot study. *Endoscopy* **32**, 42–48 (2000).
15. Finger, V. H., Mang, T. S. & Henderson, B. W. Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice. *Cancer Res.* **48**, 3350–3354 (1988).
16. Dong, G. C., Hu, S. X., Zhao, G. Y., Gao, S. Z. & Wu, L. R. Experimental study on cytotoxic effects of hyperbaric oxygen and photodynamic therapy on mouse transplanted tumour. *Chin Med. J. (Engl)* **100**, 697–702 (1987).
17. Thom, S. R. Hyperbaric oxygen: its mechanisms and efficacy. *Plast. Reconstr. Surg.* **127**, 131–141 (2011).
18. Castro, C. I. & Briceno, J. C. Perfluorocarbon-based oxygen carriers: review of products and trials. *Artif. Organs* **34**, 622–634 (2010).
19. Fuchs, J. & Thiele, J. The role of oxygen in cutaneous photodynamic therapy. *Free Radic. Biol. Med.* **24**, 835–847 (1998).
20. Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. *Nat. Rev. Drug Discov.* **7**, 771–782 (2008).
21. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Med. Pharm. Sci.* **5**, 505–515 (2008).
22. Juwenie, A., Nielsen, K. P. & Moan, J. Biophysical aspects of photodynamic therapy. *J. Environ. Pathol. Toxicol. Oncol.* **25**, 7–28 (2008).
23. Zhou, Y. et al. Microbubbles from gas-generating perfluorohexane nanoemulsions for targeted temperature-sensitive ultrasonography and synergistic HIFU ablation of tumours. *Adv. Mater.* **25**, 4123–4130 (2013).
24. Srivivas, M., Boehm-Sturm, P., Fidgler, C. G., de Vries, I. J. & Hoehn, M. Labeling cells for in vivo tracking using F-19 MRI. *Biomaterials* **33**, 8830–8840 (2012).
25. Ahrens, E. T. & Bulte, J. W. M. Tracking immune cells in vivo using magnetic resonance imaging. *Nat. Rev. Immunol.* **13**, 753–763 (2013).

**Acknowledgements**

This project was supported by National Natural Science Foundation (No. 81202474, 8127464 and 81473146), Changzhou Special Project of Biotechnology and Biopharmacy (No.CE2010506), and Social Development of National Science Foundation of Jiangsu Province (No. BE2015674). J.W. is sponsored by Qing Lan Project.

**Author contributions**

Y.C.J.W. and Y.H. designed the study; H.C.and K.W. performed the animal experiment; C.J. and W.H. performed the cell experiment; J.W. and Y.C. wrote the paper. H.C.,X.Q.,A.Y. and Y.H. edited the manuscript; J.W. and Y.H. supervised the whole project.

**Additional information**

**Supplementary Information** accompanies this paper at http://www.nature.com/naturecommunications

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission** information is available online at http://http://www.nature.com/ndpg

**How to cite this article:** Cheng, Y. et al. Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. *Nat. Commun.* 6:8785 doi: 10.1038/ncomms9785 (2015).